Physician profile
Daniel J Cameron
NPI 1568481893
$978.54
in general payments reported to CMS, 2019-2025
7 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $33.90 · 2021: $192 · 2022: $298 · 2023: $133 · 2024: $180 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $454.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $594.49 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Lilly USA, LLC | $165.81 | 2021-2024 | Retevmo, Jaypirca, Verzenio |
| Abbvie INC. | $103.52 | 2021-2022 | |
| Celgene Corporation | $39.08 | 2022-2025 | Reblozyl |
| Eisai INC. | $34.47 | 2021 | |
| Janssen Biotech, INC. | $25.19 | 2021 | |
| Servier Pharmaceuticals LLC | $15.98 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.